Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by Infinium Global Research on non-small cell lung cancer therapeutics market provides an in-depth analysis of segments and sub-segments in global as well as regional non-small cell lung cancer therapeutics market. The study also highlights the impact of drivers, restraints and macro indicators on the global and regional non-small cell lung cancer therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global non-small cell lung cancer therapeutics market. According to the report the global non-small cell lung cancer therapeutics market is projected to grow at a CAGR of 8% over the forecast period of 2018-2024.
The non-small cell lung cancer is a type of lung cancer arising in the epithelial tissue, and it is different than the small cell lung cancer. This non-small cell lung cancer is the most common lung cancer among all types of lung cancers. Most often, treatment for NSCLC uses a combination of 2 chemo drugs. Studies have shown that adding a third chemo drug doesn’t add many benefits and is likely to cause more side effects. The report defines the market of non-small cell lung cancer on the basis of the treatment types including early/non-metastatic NSCLC, advanced/metastatic NSCLC, EGFR mutations, ALK gene rearrangements, and other treatment options.
The air pollution is increasing rapidly all over the globe. According to the world health organization, outdoor air pollution is the main cause of lung cancer. Rising smoking habit among the population and the increasing air population drives the market growth of non-small cell lung cancer therapeutics market. The American Cancer Society’s recorded an average of about 2,34,030 new cases of lung cancer and about 1,54,050 deaths from lung cancer up to2018. Moreover, the ongoing R&D on non-small cell lung cancer therapies, growing focus on healthcare sectors, and the introduction of new drugs are projected to create more opportunities in this market in upcoming years.
Geographically, North America dominates the market of non-small cell lung cancer therapeutics market. The government of North America supports the research activity that results in the up gradation of existing drugs and the development of new advanced and effective drugs are increasing. The presence of major players and increased advancements in these sectors are expected to boost the market of non-small cell lung cancer therapeutics in this region between the period of 2018 to 2024.
The report on global non-small cell lung cancer therapeutics market covers segments such as drug class. On the basis of drug class, the global non-small cell lung cancer therapeutics market is categorized into angiogenesis inhibitor, kinase inhibitor, epidermal growth factor receptor blocker, folate antimetabolites, PD-1/ PD-L1 inhibitor, and microtubule stabilizer.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience growth at a CAGR of x.x% over the period of 2018-2024.
The report provides profiles of the companies in the global non-small cell lung cancer therapeutics market such as Celgene Corporation, Bristol-Myers Squibb, Novartis AG, Eli Lilly, Pfizer, straZeneca Plc, Merck KGaA, F. Hoffmann-La Roche Ltd, AstraZeneca, and Orion Corporation.
The report provides deep insights on demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global non-small cell lung cancer therapeutics market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of non-small cell lung cancer therapeutics market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the non-small cell lung cancer therapeutics market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. This report will help manufacturers, suppliers and distributors of the non-small cell lung cancer therapeutics market to understand the present and future trends in this market and formulate their strategies accordingly.
Please Choose One of them.